Pharming presents leniolisib pediatric APDS data at Clinical Immunology Society meeting

Pharming Group NV Sponsored ADR

Pharming Group NV Sponsored ADR

PHAR

0.00
  • Pharming Group to present leniolisib data at Clinical Immunology Society 2026 Annual Meeting, scheduled May 6-9 in New Orleans.
  • Program includes interim pediatric long-term extension results in APDS, plus clinical experience from expanded-access use in CVID and CVID-like disorders.
  • Poster sessions listed for May 7-8, including pediatric APDS symptom reporting analyses and a phase 2 study design update in primary immunodeficiencies with enhanced PI3K pathway signaling.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070105PRIMZONEFULLFEED1001180429) on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.